Neumora Therapeutics, Inc.'s market cap is currently ―. The company's EPS TTM is $-1.519; its P/E ratio is -6.94; Neumora Therapeutics, Inc. is scheduled to report earnings on March 7, 2024, and the estimated EPS forecast is $-0.55. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Dec 22
Income Statement	-
Total Revenue	-	-	-
Gross Profit	-	-	-
EBIT	-	-	-
EBITDA	-	-	-
Net Income Common Stockholders	£ -53.03M	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	£ 509.56M	£ 324.20M	£ 371.88M
Total Assets	£ 544.75M	£ 359.95M	£ 426.23M
Total Debt	£ 6.14M	£ 6.82M	£ 8.44M
Net Debt	£ -503.42M	£ -317.38M	£ -363.44M
Total Liabilities	£ 32.06M	£ 29.81M	£ 29.40M
Stockholders Equity	£ 512.69M	£ 330.15M	£ 396.84M
Cash Flow	-
Free Cash Flow	£ -47.81M	-	-
Operating Cash Flow	£ -47.77M	-	-
Investing Cash Flow	£ 23.82M	-	-
Financing Cash Flow	£ 232.02M	-	-

Currency in GBP

Neumora Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Neumora Therapeutics, Inc. Debt to Assets

Balance Sheet >

Neumora Therapeutics, Inc. Cash Flow

Cash Flow >

Neumora Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing